News
MDXG
7.78
+0.91%
0.07
Weekly Report: what happened at MDXG last week (0918-0922)?
Weekly Report · 2d ago
Weekly Report: what happened at MDXG last week (0911-0915)?
Weekly Report · 09/18 09:55
Weekly Report: what happened at MDXG last week (0904-0908)?
Weekly Report · 09/11 09:54
Weekly Report: what happened at MDXG last week (0828-0901)?
Weekly Report · 09/04 16:09
Weekly Report: what happened at MDXG last week (0821-0825)?
Weekly Report · 08/28 09:57
Commit To Purchase MiMedx Group At $5, Earn 8.3% Annualized Using Options
NASDAQ · 08/08 17:45
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 08/02 13:06
Mizuho Maintains Buy on MiMedx Group, Raises Price Target to $12
Benzinga · 08/02 11:58
H.C. Wainwright Sticks to Their Buy Rating for MiMedx Group (MDXG)
TipRanks · 08/02 10:15
HC Wainwright & Co. Maintains Buy on MiMedx Group, Raises Price Target to $11
Benzinga · 08/02 10:11
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 08/01 21:32
Mimedx Group Inc: Current report
Press release · 08/01 21:01
Mimedx Group Inc: Quarterly report
Press release · 08/01 21:01
MiMedx Group GAAP EPS of $0.00 beats by $0.03, revenue of $81.3M beats by $6.47M
Seeking Alpha · 08/01 20:19
More
Webull provides a variety of real-time MDXG stock news. You can receive the latest news about Mimedx Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About MDXG
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. The Company is focused on addressing unmet clinical needs in the areas of Advanced Wound Care, Surgical Recovery, and osteoarthritis. The Company operates through two segments: Wound and Surgical, and Regenerative Medicine. The Wound and Surgical segment focuses on the Advanced Wound Care and Surgical Recovery markets. Its platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc. The Regenerative Medicine segment focuses solely on Regenerative Medicine technologies. The Company’s product portfolio and pipeline include EPIFIX, AMNIOFIX, mDHACM, AMNIOBURN, EPICORD and AMNIOCORD, AXIOFILL, and AMNIOEFFECT.